# Incyte Drops Plans for Phase 3 MAESTRA-3 Ovarian Cancer Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/57050
Published: 2026-11-13T22:17:53.000Z
Updated: 2026-11-13T22:17:53.000Z
Section: Business

> The study was designed to test INCB123667 with bevacizumab as first-line maintenance therapy for ovarian cancer.

Incyte has decided not to move ahead with its planned Phase 3 MAESTRA-3 trial, which was designed to test a drug combination as first-line maintenance therapy for ovarian cancer.

The study would have evaluated INCB123667 with bevacizumab.